Published in
Impact Journals, Oncotarget, 20(5), p. 10034-10047, 2014
Links
- ORCID
- ORCID
- Impact Journals
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net]
- [thescholarship.ecu.edu] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
Journal article published in 2014 by
Carolina Simioni 
,
Alice Cani,
Alberto M. Martelli,
Giorgio Zauli,
Giovanna Tabellini,
James McCubrey ,
Silvano Capitani,
Luca M. Neri
,
Alice Cani,
Alberto M. Martelli,
Giorgio Zauli,
Giovanna Tabellini,
James McCubrey ,
Silvano Capitani,
Luca M. Neri
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
The PI3K/Akt/mTOR signaling cascade is a key regulatory pathway controlling cell growth and survival, and its dysregulation is a reported feature of B-precursor acute lymphoblastic leukemia (B-pre ALL).